Sign in with Google
bearish
Legend Biotech (传奇生物) Follow-On Offering - Untimely Raise
352 Views15 Dec 2021 08:32
Legend Biotech Corp (LEGN US) a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is looking US$300m in its follow-on offering.
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 5-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction26 Jul 2022
- Legend Biotech (传奇生物) Follow-On Offering - Untimely Raise15 Dec 2021
- Legend Biotech (传奇生物) IPO Trading: +27% Upside from Pricing05 Jun 2020
- Legend Biotech (传奇生物) Pre-IPO: A Good Deal for the Promising CAR-T01 Jun 2020
x